Japanese Journal of Cancer and Chemotherapy最新文献_第6页

[Cardio-Oncology-Addressing Unmet Needs through Guidelines and Evidence Gaps]. [心脏肿瘤学-通过指南和证据差距解决未满足的需求]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-05-01

Kazuhiro Sase

引用次数: 0

[Characteristics of Cardiotoxicity in Breast Cancer Treatment and the Importance of Onco-Cardiology]. [乳腺癌治疗中心脏毒性的特点及肿瘤学的重要性]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-05-01

Masataka Sawaki

{"title":"[Characteristics of Cardiotoxicity in Breast Cancer Treatment and the Importance of Onco-Cardiology].","authors":"Masataka Sawaki","doi":"","DOIUrl":"","url":null,"abstract":"Cardiovascular disease and dysfunction in cancer patients is often a medical problem. Cancer therapeutics related cardiac dysfunction(CTRCD)has long been known as late toxicity of anthracycline use and irradiation of the preserved breast and chest wall in breast cancer patients, CTRCD has received increasing attention, but there is still little evidence for prevention or prediction. Breast cancer has a good treatment outcome, and there is a need to address late cardiotoxicity. In recent years, the introduction of new drugs has forced us to deal with patients with new cardiotoxic and cardiovascular complications, such as myocarditis, which, combined with the increase in the number of cancer survivors with improved outcomes, has increased the number of situations requiring the concurrent consultation of oncologists and cardiologists. The goal is to improve life outcomes with optimal cancer treatment while reducing cardiac disease through appropriately timed interventions. Since drugs play different roles in initial treatment aiming for cure and palliative drug therapy for metastatic or recurrent breast cancer, cardiotoxicity should be discussed separately in close communication with cardiologists when considering the risk-benefit ratio. Discussions regarding the continuation of cardiac treatment and cancer treatment need to be done separately in'close collaboration'between oncologists and cardiologists.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 5","pages":"389-393"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144152199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Complete Response Achieved by Gemcitabine+Cisplatin+Durvalumab Therapy for Lymph Node Recurrence of Intraductal Cholangiocarcinoma-A Case Report]. 【吉西他滨+顺铂+杜伐单抗治疗导管内胆管癌淋巴结复发完全缓解1例报告】。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-05-01

Noriki Mitsui, Masahiro Fukada, Takeshi Horaguchi, Katsutoshi Murase, Nobuhisa Matsuhashi

引用次数: 0

[Efficacy of Scalp Cooling Therapy for Hair Loss Prevention and Recovery in Patients with Breast Cancer Receiving Chemotherapy at Our Hospital]. [头皮冷却疗法在我院乳腺癌化疗患者预防和恢复脱发中的疗效]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-05-01

Ayaka Tateno, Shun Kudo, Takatoshi Makino

{"title":"[Efficacy of Scalp Cooling Therapy for Hair Loss Prevention and Recovery in Patients with Breast Cancer Receiving Chemotherapy at Our Hospital].","authors":"Ayaka Tateno, Shun Kudo, Takatoshi Makino","doi":"","DOIUrl":"","url":null,"abstract":"We herein report the hair loss and recovery rates of patients treated with scalp cooling therapy at our hospital. Overall, 14 Japanese women with breast cancer who were scheduled to undergo chemotherapy and who used the Paxman Scalp Cooling SystemTM between May 2022 and May 2023 participated in our study. We retrospectively evaluated the efficacy of the scalp cooling therapy in preventing hair loss. We also assessed the extent of hair recovery at 1, 3, 6, and 12 months after chemotherapy using the scalp cooling therapy. Data were evaluated using the Dean scale. Post-chemotherapy, 8 patients (57.1%)experienced Grade 4 hair loss(defined as hair loss of >75%). No statistically significant difference was observed. A month after chemotherapy ended, the number of patients with Grade 4 hair loss reduced to 2/14(14.3%). No patient experienced Grade 4 hair loss after 3 months. By 6 months, all patients had recovered their pre-treatment hair volume. One year after chemotherapy, hair volume was sufficiently preserved. Our data indicate that scalp cooling during chemotherapy can reduce hair loss and accelerate hair regrowth.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 5","pages":"403-406"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144152208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of Invasive Lobular Carcinoma Complicated by Disseminated Carcinomatosis of the Bone Marrow with Severe Bone Marrow Fibrosis and Acute Splenomegaly]. 浸润性小叶癌合并弥散性骨髓癌伴严重骨髓纤维化急性脾肿大1例。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-05-01

Yumi Nozaki, Minori Yamamuro, Noriyoshi Tanaka, Nobuyuki Kamo, Mari Ueno, Tsuyoshi Ishida, Juichiro Konishi

{"title":"[A Case of Invasive Lobular Carcinoma Complicated by Disseminated Carcinomatosis of the Bone Marrow with Severe Bone Marrow Fibrosis and Acute Splenomegaly].","authors":"Yumi Nozaki, Minori Yamamuro, Noriyoshi Tanaka, Nobuyuki Kamo, Mari Ueno, Tsuyoshi Ishida, Juichiro Konishi","doi":"","DOIUrl":"","url":null,"abstract":"A 60-year-old female presented at our hospital with a mass in her left breast. Needle biopsy of the breast mass confirmed a diagnosis of invasive lobular carcinoma, and the patient underwent left mastectomy and axillary lymph node dissection. The patient received adjuvant chemotherapy and was started on continuous endocrine therapy. Three years post-surgery, she experienced recurrence of multiple bone metastases and received a combination of hormone therapy and selective cyclin-dependent kinases 4/6 inhibitors. Therapeutic efficacy was poor, allowing bone metastases to spread. Four months post-recurrence, blood tests revealed moderate thrombocytopenia. Despite the switch to chemotherapy, the patient's platelet count did not recover. CT revealed splenomegaly, which was not present three months earlier. Bone marrow biopsy revealed severe myelofibrosis with infiltration of small dysplastic cells into dense fibrotic tissue. The patient developed microangiopathic hemolytic anemia, but DIC was not observed during the course of the disease. Ten months after recurrence, a brain metastasis was detected, and the patient died the following month.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 5","pages":"411-413"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144152151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Metastatic Squamous Cell Carcinoma with Unknown Primary Origin in the Mediastinal Lymph Node]. [原发来源不明的纵隔淋巴结转移性鳞状细胞癌]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-05-01

Yuko Harada, Noriki Kamiya, Makoto Ohbu, Masashi Ogiso, Hinako Maeda, Hiroyuki Sako, Nobushige Yabe, Keiichi Sotome, Yoshiyuki Ishii, Ichiro Maeda

引用次数: 0

[A Case of Rectal Metastasis from Prostate Cancer]. 前列腺癌直肠转移1例

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-05-01

Tasuku Nishitani, Kiyonori Kanemitsu, Chonsu Kin, Mayumi Inaba, Chiharu Tamura, Takeshi Iwasaki

引用次数: 0

[Problem in the Prophylactic Management of Perioperative Venous Thromboembolism(VTE)in Japanese Cancer Patients]. [日本癌症患者围手术期静脉血栓栓塞（VTE）的预防管理问题]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-05-01

Taishi Hata

{"title":"[Problem in the Prophylactic Management of Perioperative Venous Thromboembolism(VTE)in Japanese Cancer Patients].","authors":"Taishi Hata","doi":"","DOIUrl":"","url":null,"abstract":"In the field of oncological cardiology, the management of venous thromboembolism(VTE)in cancer patients is critical. Cancer patients have a 4-7 fold increased risk of developing VTE compared to non-cancer patients, and once symptomatic pulmonary thromboembolism(PTE)occurs, the mortality rate is high, about 20 according one report. The oncological cardiology guidelines also list future research questions concerning VTE management during chemotherapy. However, cancer patient treatment is not solely pharmacological; particularly in gastrointestinal surgery, operative treatment is crucial, and VTE prophylaxis is important due to the increased incidence during the perioperative period. An important consideration in devising strategies is that there are racial differences in the frequency of VTE occurrences and bleeding tendencies due to anticoagulation therapy. However, data in this field of our country is limited, and currently, Japanese guideline are based on Western guidelines adapted to suit the situation of Japan. Reviewing past data, the risk of VTE in Japanese is generally lower compared to Caucasian populations. In particular, as anticoagulant therapy can also influence postoperative bleeding, its indication requires thorough verification. It is considered one of the crucial challenges in the field of oncological cardiology to construct optimal prophylactic and management methods based on Japanese data moving forward.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 5","pages":"394-397"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144152226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Prediction of Anti-Tumor Immunity-Significance of a Novel Th1-Like CD4+ T-Cell Cluster]. [一种新型th1样CD4+ t细胞群的抗肿瘤免疫预测意义]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-05-01

Hiroshi Kagamu

{"title":"[Prediction of Anti-Tumor Immunity-Significance of a Novel Th1-Like CD4+ T-Cell Cluster].","authors":"Hiroshi Kagamu","doi":"","DOIUrl":"","url":null,"abstract":"Anti-tumor T-cell immunity invigorated by immune checkpoint inhibitors(ICI)mediate anti-tumor effects over the years, resulting in long-term survival. However, the ICI effects vary greatly from patient to patient, and accurate prediction of the effects is still not possible. Long-term anti-tumor T-cell immunity requires that the cancer immunity cycle remain in operation. It is CD4+ T cells that direct the priming, migration and infiltration abilities, and the acquisition of cytolytic functions of CD8+ T cells and drive the cancer immunity cycle. CD4+ T cells undergo functional differentiation called polarization when they are primed in lymph nodes, and they perform their predetermined functions throughout the body. For this reason, the information collected from peripheral blood can reflect the tumor microenvironments. It has been shown in mouse models that CD4+ T cells that polarize into type 1 helper T cells(Th1)are important for anti-tumor immunity. On the other hand, it has been reported that CD4+ T cells that are responsible for the anti-tumor effects of anti-PD-1 antibody and anti-CTLA-4 antibody therapy are Th1-like, but differ from canonical Th1. In this paper, we will discuss the properties of the novel Th1-like CD4+ T-cell cluster discovered by the authors, and the prediction performance of anti-tumor T-cell immunity.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 5","pages":"377-382"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144152215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Development of Oncolytic Virus Immunotherapy to Improve the Immunosuppressive Microenvironment in Pancreatic Cancer]. [溶瘤病毒免疫治疗改善胰腺癌免疫抑制微环境的进展]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-05-01

Kanto Suemori, Hiroshi Tazawa, Motohiko Yamada, Naohiro Okada, Satoru Kikuchi, Shinji Kuroda, Kazuhiro Noma, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

引用次数: 0